Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Solid Biosciences Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- +4 vs. Q4 2022
- Shares held
- 15.8M
- +464.7K (+3.0%) vs. Q4 2022
- Total value
- $74.8M
- −$10.9M (−12.7%) vs. Q4 2022
- New holders
- 10
- 8 more added
- Sold out
- 6
- 9 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLDB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 157 | $1.14B |
| Q1 2026 | 150 | $717.4M |
| Q4 2025 | 132 | $459.2M |
| Q3 2025 | 129 | $505.2M |
| Q2 2025 | 116 | $403.4M |
| Q1 2025 | 125 | $293.2M |
| Q4 2024 | 90 | $145.3M |
| Q3 2024 | 92 | $249.8M |
| Q2 2024 | 80 | $213.2M |
| Q1 2024 | 56 | $465.9M |
| Q4 2023 | 40 | $102.2M |
| Q3 2023 | 37 | $40.7M |
| Q2 2023 | 36 | $85.6M |
| Q1 2023 | 39 | $74.8M |
| Q4 2022 | 35 | $85.6M |
| Q3 2022 | 58 | $33.4M |
| Q2 2022 | 67 | $39.5M |
| Q1 2022 | 78 | $83.3M |
| Q4 2021 | 82 | $132.2M |
| Q3 2021 | 91 | $184.3M |
| Q2 2021 | 92 | $293.4M |
| Q1 2021 | 104 | $437.6M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Solid Biosciences Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 6 | $28 | 0.00% | 00.0% | Unchanged |
| Baker Avenue Asset Management, LP | 66 | $313 | 0.00% | +66 | New |
| Wells Fargo & Company | 123 | $583 | 0.00% | +29+30.9% | Added |
| First Manhattan Co | 133 | $630 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 158 | $748 | 0.00% | +128+426.7% | Added |
| UBS Group AG | 166 | $787 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 254 | $1.00K | 0.00% | −70−21.6% | Reduced |
| JPMorgan Chase & Co | 133 | $1.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 274 | $1.30K | 0.00% | −13−4.5% | Reduced |
| FMR LLC | 300 | $1.42K | 0.00% | +300 | New |
| Manchester Capital Management LLC | 1,000 | $4.74K | 0.00% | 00.0% | Unchanged |
| Lazard Asset Management LLC | 2,089 | $9.00K | 0.00% | +2,089 | New |
| Bank of America Corp | 2,326 | $11.0K | 0.00% | −397−14.6% | Reduced |
| Barclays PLC | 4,417 | $20.9K | 0.00% | −20−0.5% | Reduced |
| Morgan Stanley | 4,618 | $21.9K | 0.00% | −69−1.5% | Reduced |
| Charles Schwab Investment Management Inc | 10,000 | $47.4K | 0.00% | +10,000 | New |
| Northern Trust Corp | 11,062 | $52.4K | 0.00% | +11,062 | New |
| Citadel Advisors LLC | 11,756 | $55.7K | 0.00% | +11,756 | New |
| CIBC Asset Management Inc | 12,083 | $57.3K | 0.00% | +12,083 | New |
| State Street Corp | 13,394 | $63.5K | 0.00% | −9,253−40.9% | Reduced |
| Susquehanna International Group, LLP | 18,690 | $88.6K | 0.00% | +18,690 | New |
| Tower Research Capital LLC (TRC) | 23,950 | $113.0K | 0.00% | +12,099+102.1% | Added |
| Bridgeway Capital Management, LLC | 34,686 | $164.4K | 0.00% | +15,000+76.2% | Added |
| Renaissance Technologies LLC | 38,763 | $184.0K | 0.00% | −13,000−25.1% | Reduced |
| Geode Capital Management, LLC | 41,911 | $198.7K | 0.00% | +2,830+7.2% | Added |
| Dimensional Fund Advisors LP | 56,335 | $267.0K | 0.00% | +597+1.1% | Added |
| BlackRock Inc. | 138,761 | $657.7K | 0.00% | −5,303−3.7% | Reduced |
| Great Point Partners LLC | 210,405 | $997.3K | 0.20% | +210,405 | New |
| Vanguard Group Inc | 222,697 | $1.06M | 0.00% | 00.0% | Unchanged |
| Pura Vida Investments, LLC | 224,902 | $1.07M | 0.11% | +224,902 | New |
| Caas Capital Management LP | 244,518 | $1.16M | 0.38% | −39,169−13.8% | Reduced |
| Finepoint Capital LP | 488,857 | $2.32M | 0.89% | +270,295+123.7% | Added |
| Alyeska Investment Group, L.P. | 646,604 | $3.06M | 0.03% | +106,457+19.7% | Added |
| Artal Group S.A. | 909,219 | $4.31M | 0.26% | 00.0% | Unchanged |
| Laurion Capital Management LP | 928,169 | $4.40M | 0.20% | 00.0% | Unchanged |
| Camber Capital Management LP | 1,418,439 | $6.72M | 0.23% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,130,422 | $14.8M | 1.85% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 3,426,286 | $16.2M | 0.37% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 3,495,933 | $16.6M | 0.49% | 00.0% | Unchanged |
| K2 Principal Fund, L.P. | 0 | $0 | 0.00% | −342,271−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −12,846−100.0% | Sold out |
| Old Well Partners, LLC | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −9,507−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −1,367−100.0% | Sold out |
| Investors Research Corp | 0 | $0 | 0.00% | −13−100.0% | Sold out |